Compare

Zealand Pharma A/S/€ZEAL

1D1W1M3M6MYTD1Y5YMAX

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines. The company is headquartered in Copenhagen, Denmark, and operates in the pharmaceutical industry. Zealand Pharma's portfolio includes several marketed products and a robust pipeline addressing gastrointestinal, metabolic, and other specialty disease areas. Notably, their therapeutic offerings include dasiglucagon for severe hypoglycemia and other proprietary peptides. The company leverages its unique peptide platform to enhance drug discovery and development processes, aiming to deliver targeted treatments with potentially improved safety and efficacy profiles.
Ticker
€ZEAL
Sector
Health
Primary listing
XGAT
Employees
578
Headquarters
Søborg, Denmark
Website
www.zealandpharma.com

ZEAL Metrics

BasicAdvanced
€2.2B
6.42
€5.15
0.59
-

What the Analysts think about ZEAL

Analyst ratings (Buy, Hold, Sell) for Zealand Pharma A/S stock.
Analyst projections of the future price of Zealand Pharma A/S stock.

Bulls say / Bears say

Petrelintide’s Phase 2 study showed up to 10.7% weight loss after 42 weeks, with gastrointestinal side effects broadly similar to placebo and no GI-related dropouts at the most effective dose. The partners have moved it into Phase 3, giving Zealand a lead asset with a potentially more tolerable profile. (Zealand Pharma)
Survodutide may retain value in liver disease: its Phase 3 MASLD study met its primary endpoints, and six in ten treated participants achieved liver-fat normalisation. Boehringer has also expanded the development programme with four additional Phase 3b trials. (Zealand Pharma)
Zealand had DKK 14.5 billion in cash at the end of June 2026 and raised another $100 million by selling part of its rusfertide royalty rights. That gives it substantial funding to advance its pipeline without relying solely on near-term equity issuance. (Zealand Pharma, Royalty Pharma)
Survodutide’s Phase 3 results raise a serious tolerability concern: 18% of treated patients stopped because of gastrointestinal side effects, and vomiting was reported by 39%. These rates could limit how well the drug competes in obesity treatment, even though the trial met its main endpoints. (Fierce Biotech)
Petrelintide’s Phase 2 results in people with type 2 diabetes showed up to 9.2% weight loss at 28 weeks, but analysts were disappointed by the weight-loss magnitude and its HbA1c reduction of up to 0.65%, below the levels cited for leading rival therapies. This could limit its appeal in a large patient group, despite low treatment discontinuation. (BioSpace)
The next major value drivers may take time to arrive: Barclays saw few catalysts likely to change the investment case over the following 12 months and noted that Lilly could report pivotal obesity data ahead of Zealand’s petrelintide programme. That leaves Zealand exposed to competitive advances before its own late-stage data can clarify its prospects. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.

ZEAL Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

ZEAL Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.